Search

Pituitary tumours: why are they so often missed?

Part 2: Clinical varieties, anatomical considerations and case report (see also Part 1 and Part 3) For ophthalmologists there are four types of pituitary tumour to be considered, three of which are named according to the hormone secreted, along with...

Redeployment during the COVID-19 pandemic: personal accounts from four ophthalmology trainees

We once believed that the coronavirus would not penetrate the safe confines of the United Kingdom, like so many outbreaks before this. Once the news came that this pandemic descended into our hospitals, the anxieties about redeployment began. Many of...

DR-NET National DR Workshop in Tanzania: Policy, training and technology

Diabetic retinopathy (DR) is a leading cause of moderate to severe visual impairment (VI) and blindness worldwide, posing a significant public health challenge. As the prevalence of diabetes continues to rise globally, particularly in low- and middle-income countries (LMICs), the...

VISION 2020 LINKS: Retinoblastoma 
in Africa

The VISION 2020 LINKS Programme is part of the ‘VISION 2020: The Right to Sight’ global initiative to eliminate avoidable blindness [1]. The LINKS Programme works with overseas eye departments to help identify priorities and match their priority needs with...

Regulatory drug evaluations and expedited review initiatives: EU and US perspectives

The European Medicines Agency (EMA) and United States Food and Drug Administration (FDA) each conduct independent assessments of benefit-risk profile when evaluating applications to market new or modified medicines, and their respective decision-making is guided by distinct legislation, procedures and...